Program
Gemcitabine
Also written as “gemcitabine”, “gemcitabine hydrochloride” and “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”.
Its studies are mostly in Pancreatic Neoplasms · Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Neoplasms · Biliary Tract Neoplasms, led by 30 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 681 open or running | phase 3since Nov 6, 2000 | Nov 6, 2000 | May 2027phase 2 · NCT05999994 |
| Hoffmann-La Roche | 181 open or running | phase 4since Mar 19, 2008 | Apr 17, 2007 | Mar 22, 2027phase 1 · NCT06624085 |
| Pfizer | 50 open or running | phase 3since Jan 21, 2000 | Jan 21, 2000 | none ahead |
| GlaxoSmithKline | 40 open or running | phase 2since May 23, 2003 | May 23, 2003 | none ahead |
| Amgen | 30 open or running | phase 2since Jul 5, 2000 | Jul 5, 2000 | none ahead |
| Astellas Pharma | 20 open or running | phase 1since Apr 9, 2002 | Apr 9, 2002 | none ahead |
| NovoCure | 20 open or running | phase 2since Oct 23, 2013 | Oct 23, 2013 | none ahead |
| Pierre Fabre | 20 open or running | phase 2since Apr 16, 2012 | Apr 16, 2012 | none ahead |
| Sarah Cannon Research Institute | 20 open or running | phase 2since Apr 4, 2008 | Apr 4, 2008 | none ahead |
| theriva-biologics-sl | 20 open or running | phase 1since Jan 21, 2014 | Jan 21, 2014 | none ahead |
| academic-thoracic-oncology-medical-investigators-consortium | 10 open or running | phase 2since Mar 24, 2016 | Mar 24, 2016 | none ahead |
| bebetter-med-inc | 10 open or running | phase 2since Nov 11, 2024 | Nov 11, 2024 | none ahead |
| Betta Pharmaceuticals | 10 open or running | phase 4since Jul 16, 2014 | Jul 16, 2014 | none ahead |
| coherus-oncology-inc | 11 open or running | phase 4since Jun 10, 2024 | Jun 10, 2024 | Dec 2027phase 4 · NCT06457503 |
| ebg-medaustron-gmbh | 11 open or running | no phasesince May 10, 2021 | May 10, 2021 | Dec 31, 2026NCT04894643 |
| Eisai | 10 open or running | phase 2since May 17, 2010 | May 17, 2010 | none ahead |
| hope-cancer-institute-inc | 10 open or running | phase 2since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| jiangsu-healthy-life-innovation-medical-technology-co-ltd | 11 open or running | no phasesince Sep 20, 2024 | Sep 20, 2024 | none ahead |
| meyer-pharmaceuticals | 10 open or running | phase 2since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| novacea | 10 open or running | phase 2since Sep 26, 2007 | Sep 26, 2007 | none ahead |
| Otsuka | 10 open or running | phase 3since Jun 2, 2000 | Jun 2, 2000 | none ahead |
| Pharmacosmos | 10 open or running | phase 2since Nov 18, 2016 | Nov 18, 2016 | none ahead |
| pharmatech-oncology | 10 open or running | phase 2since Dec 7, 2001 | Dec 7, 2001 | none ahead |
| relmada-therapeutics-inc | 11 open or running | phase 2since Aug 8, 2024 | Aug 8, 2024 | Nov 2027phase 2 · NCT06663137 |
| renovorx | 10 open or running | phase 1since Sep 8, 2014 | Sep 8, 2014 | none ahead |
| shanghai-miracogen-inc | 11 open or running | phase 3since Feb 22, 2023 | Feb 22, 2023 | none ahead |
| Sino Biopharmaceutical | 10 open or running | phase 3since Jul 17, 2018 | Jul 17, 2018 | none ahead |
| smartwise-sweden-ab | 11 open or running | phase 2since Apr 5, 2026 | Apr 5, 2026 | Dec 2027phase 2 · NCT07575191 |
| Swedish Orphan Biovitrum | 10 open or running | phase 3since Feb 5, 2003 | Feb 5, 2003 | none ahead |
| synergene-therapeutics-inc | 11 open or running | phase 2since Dec 18, 2014 | Dec 18, 2014 | Dec 2026phase 2 · NCT02340117 |
Also a collaborator on its studies: Ono Pharmaceutical, baili-bio-chengdu-pharmaceutical-co-ltd, AbbVie, Bristol-Myers Squibb, criterium-inc, AstraZeneca, pharmabio-development-inc, Johnson & Johnson, ppd-development-lp, Merck, Sanofi and prologue-research-international.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Jun 20, 2007.
- Nov 7, 2017Phase 2 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT03337698 · 314 enrolled · United States, Australia, France and more
- Dec 22, 2017Phase 2 study in Uterine Cervical NeoplasmsHoffmann-La Roche · NCT03386721 · 256 enrolled · United States, Belgium, France and more
- Jul 17, 2018Sino Biopharmaceutical's first study: phase 3 study in Nasopharyngeal CarcinomaNew to Sino BiopharmaceuticalSino Biopharmaceutical · NCT03601975 · 336 enrolled · China
- Mar 8, 2019Phase 2 study in Carcinoma, Transitional CellHoffmann-La Roche · NCT03869190 · 272 enrolled · United States, France, Greece and more
- May 10, 2021ebg-medaustron-gmbh's first study: no phase study in Pancreatic NeoplasmsNew to ebg-medaustron-gmbhebg-medaustron-gmbh · NCT04894643 · 10 planned · Austria
- Feb 22, 2023shanghai-miracogen-inc's first study: phase 3 study in Advanced or Metastatic Urothelium CancerNew to shanghai-miracogen-incshanghai-miracogen-inc · NCT05754853 · 290 planned · China
- Aug 14, 2023Phase 2 study in NeoplasmsEli Lilly · NCT05999994 · 105 planned · United States, Australia, Belgium and more
- Feb 29, 2024Phase 2 study in Pancreatic NeoplasmsNovoCure · NCT06390059 · 84 enrolled · Czechia, Germany, Spain and more
- Jun 10, 2024coherus-oncology-inc's first study: phase 4 study in Nasopharyngeal NeoplasmsNew to coherus-oncology-inccoherus-oncology-inc · NCT06457503 · 100 planned · United States, Canada
- Aug 8, 2024relmada-therapeutics-inc's first study: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNew to relmada-therapeutics-increlmada-therapeutics-inc · NCT06663137 · 70 planned · Israel
- Sep 20, 2024jiangsu-healthy-life-innovation-medical-technology-co-ltd's first study: no phase study in Biliary Tract NeoplasmsNew to jiangsu-healthy-life-innovation-medical-technology-co-ltdjiangsu-healthy-life-innovation-medical-technology-co-ltd · NCT06611345 · 60 planned · China
- Oct 1, 2024Phase 1 study in LymphomaHoffmann-La Roche · NCT06624085 · 50 enrolled · United States, Puerto Rico
- Nov 11, 2024bebetter-med-inc's first study: phase 2 study in Advanced Triple-Negative Breast CancerNew to bebetter-med-incbebetter-med-inc · NCT06685796 · 65 enrolled · China
- Apr 5, 2026smartwise-sweden-ab's first study: phase 2 study in Pancreatic Cancer Non-resectableNew to smartwise-sweden-absmartwise-sweden-ab · NCT07575191 · 9 planned · Sweden
Ahead
- Dec 2026Primary completion: phase 2 study in Pancreatic Neoplasmssynergene-therapeutics-inc · NCT02340117
- Dec 31, 2026Primary completion: no phase study in Pancreatic Neoplasmsebg-medaustron-gmbh · NCT04894643
- Mar 22, 2027Primary completion: phase 1 study in LymphomaHoffmann-La Roche · NCT06624085
- May 2027Primary completion: phase 2 study in NeoplasmsEli Lilly · NCT05999994
TargetBeta
“Ribonucleoside-diphosphate reductase RR1 inhibitor”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Hydroxyurearule | Norgine | phase 4 | 15 |
Studies
The newest 60 of 128 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07575191Pancreatic Cancer Non-resectable · Sweden | 2 | Recruiting | smartwise-sweden-ab | Dec 2027 | 9 |
| NCT06685796Advanced Triple-Negative Breast Cancer · China | 2 | Completed | bebetter-med-inc | Apr 20, 2026 | 65 |
| NCT06624085Lymphoma · United States, Puerto Rico | 1 | Active, not recruiting | Hoffmann-La Roche | Mar 22, 2027 | 50 |
| NCT06611345Biliary Tract Neoplasms · China | – | Recruiting | jiangsu-healthy-life-innovation-medical-technology-co-ltd | Oct 30, 2026 | 60 |
| NCT06663137Non-Muscle Invasive Bladder Neoplasms · Israel | 2 | Recruiting | relmada-therapeutics-inc | Nov 2027 | 70 |
| NCT06457503Nasopharyngeal Neoplasms · United States, Canada | 4 | Recruiting | coherus-oncology-inc | Dec 2027 | 100 |
| NCT06390059Pancreatic Neoplasms · Czechia, Germany, Spain and more | 2 | Completed | NovoCure | Nov 18, 2025 | 84 |
| NCT05999994Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | Eli Lilly | May 2027 | 105 |
| NCT05754853Advanced or Metastatic Urothelium Cancer · China | 3 | Recruiting | shanghai-miracogen-inc | Oct 2025 | 290 |
| NCT04894643Pancreatic Neoplasms · Austria | – | Recruiting | ebg-medaustron-gmbh | Dec 31, 2026 | 10 |
| NCT03869190Carcinoma, Transitional Cell · United States, France, Greece and more | 2 | Terminated | Hoffmann-La Roche | Oct 8, 2025 | 272 |
| NCT03601975Nasopharyngeal Carcinoma · China | 3 | UNKNOWN | Sino Biopharmaceutical | Jul 30, 2020 | 336 |
| NCT03386721Uterine Cervical Neoplasms · United States, Belgium, France and more | 2 | Terminated | Hoffmann-La Roche | Dec 30, 2021 | 256 |
| NCT03337698Carcinoma, Non-Small-Cell Lung · United States, Australia, France and more | 2 | Terminated | Hoffmann-La Roche | Oct 14, 2025 | 314 |
| NCT03193190Pancreatic Adenocarcinoma · United States, Germany, Japan and more | 2 | Completed | Hoffmann-La Roche | Feb 27, 2025 | 341 |
| NCT02981342Pancreatic Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Eli Lilly | Apr 20, 2018 | 106 |
| NCT02978716Triple Negative Breast Neoplasms · United States, Belgium, Bulgaria and more | 2 | Terminated | Pharmacosmos | Jun 28, 2019 | 102 |
| NCT02941601Thoracic Neoplasms · United States, Belgium, Germany and more | 2 | Withdrawn | Eli Lilly | Dec 2017 | 0 |
| NCT03887130Breast Neoplasms | 2 | Completed | Pierre Fabre | Apr 18, 2013 | 152 |
| NCT02807636Carcinoma, Transitional Cell · United States, Australia, Belgium and more | 3 | Completed | Hoffmann-La Roche | Aug 31, 2022 | 1,213 |
| NCT02797977Fanconi Anemia · Spain, United Kingdom | 2 | Completed | GlaxoSmithKline | Apr 8, 2020 | 153 |
| NCT02723331Pancreatic Neoplasms · United States | 2 | Completed | academic-thoracic-oncology-medical-investigators-consortium | Dec 8, 2022 | 48 |
| NCT02565641Pancreatic Neoplasms · Korea, Republic of | 2 | Completed | Hoffmann-La Roche | Sep 2006 | 63 |
| NCT02340117Pancreatic Neoplasms · United States | 2 | Active, not recruiting | synergene-therapeutics-inc | Dec 2026 | 28 |
| NCT02237157Pancreatic Neoplasms · United States | 1 | Completed | renovorx | Sep 2016 | 20 |
| NCT02194556Adenocarcinoma · China | 4 | UNKNOWN | Betta Pharmaceuticals | Jul 2017 | 100 |
| NCT02045602Neoplasms · Spain | 1 | Completed | theriva-biologics-sl | May 2019 | 42 |
| NCT02045589Neoplasms · Spain | 1 | Completed | theriva-biologics-sl | Oct 2016 | 8 |
| NCT02006667Urologic Neoplasms · Germany | 2 | Completed | Hoffmann-La Roche | Jan 2010 | 13 |
| NCT01971281Pancreatic Neoplasms · Spain, Switzerland | 2 | UNKNOWN | NovoCure | Dec 2017 | 40 |
| NCT01684878Ovarian Neoplasms · Austria, Belgium, Denmark and more | 3 | Completed | Hoffmann-La Roche | Jan 30, 2015 | 208 |
| NCT01606748Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Eli Lilly | Jun 2013 | 35 |
| NCT01599013Carcinoma, Transitional Cell · France | 2 | Completed | Pierre Fabre | Oct 2013 | 69 |
| NCT01564251Lymphoma · United States, France | 1 | Completed | Hoffmann-La Roche | Jan 11, 2018 | 104 |
| NCT01359696Solid Tumor · United States, France | 1 | Completed | Hoffmann-La Roche | May 29, 2014 | 40 |
| NCT01324258Pancreatic Neoplasms · Japan | 1 | Completed | GlaxoSmithKline | Jul 8, 2013 | 19 |
| NCT01201265Breast Neoplasms · India | 2 | Completed | Hoffmann-La Roche | Apr 2015 | 40 |
| NCT01185847Non-Squamous Non-Small Cell Lung Cancer · Belgium, France, Germany and more | 2 | Completed | Hoffmann-La Roche | Sep 2012 | 90 |
| NCT01160744Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more | 2 | Completed | Eli Lilly | Jan 2014 | 280 |
| NCT01126749Urinary Bladder Neoplasms · United States, Germany, Netherlands and more | 2 | Terminated | Eisai | May 8, 2015 | 92 |
| NCT01077713Non-Squamous Non-Small Cell Lung Cancer · Italy | 2 | Completed | Hoffmann-La Roche | Jul 2014 | 86 |
| NCT01010945Adenocarcinoma · United States | 1 | Completed | Astellas Pharma | Jan 25, 2012 | 19 |
| NCT00846027Breast Neoplasms · Spain | 2 | Completed | Hoffmann-La Roche | Dec 2011 | 90 |
| NCT00821327Urothelial Cancer · United States | 2 | Completed | Sarah Cannon Research Institute | Aug 2012 | 36 |
| NCT00701558Non-small Cell Lung Cancer Metastatic · Romania | 2 | Completed | Hoffmann-La Roche | Oct 2010 | 20 |
| NCT00678977Carcinoma, Non-Small-Cell Lung · Germany, United Kingdom | 1 | Completed | GlaxoSmithKline | Mar 30, 2010 | 22 |
| NCT00656084Recurrence | 2 | Completed | Sarah Cannon Research Institute | Jan 2007 | 16 |
| NCT00642733Pancreatic Neoplasms · Mexico | 4 | Terminated | Hoffmann-La Roche | Apr 2009 | 6 |
| NCT00623233Breast Neoplasms · United States | 2 | Completed | Eli Lilly | Jan 2011 | 52 |
| NCT00615446Neoplasms · United States | 1 | Completed | Pfizer | May 2009 | 44 |
| NCT00613730Pancreatic Neoplasms | 2 | Terminated | Amgen | Apr 2009 | 3 |
| NCT00536770Pancreatic Neoplasms · United States | 2 | Suspended | novacea | 132 | |
| NCT00491127Lymphoma, Non-Hodgkin · Spain | 2 | Completed | Eli Lilly | 10 | |
| NCT00491114Urinary Bladder Neoplasms · Italy | 2 | Completed | Eli Lilly | 8 | |
| NCT00490880Urinary Bladder Neoplasms · Poland | 2 | Completed | Eli Lilly | 2 | |
| NCT00490711Carcinoma, Ovarian Epithelial · Slovakia | 2 | Completed | Eli Lilly | 7 | |
| NCT00490659Carcinoma, Non-Small-Cell Lung · Poland | 2 | Completed | Eli Lilly | 13 | |
| NCT00490399Biliary Tract Carcinoma · Korea, Republic of | 2 | Completed | Eli Lilly | 39 | |
| NCT00489996Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Eli Lilly | 100 | |
| NCT00489983Carcinoma, Non-Small-Cell Lung · Germany, Italy, United Kingdom | 2 | Completed | Eli Lilly | 91 |
How it is read
Names in the registry
- “Gemcitabine”, 113 entries
- “gemcitabine”, 52 entries
- “gemcitabine hydrochloride”, 17 entries
- “AK112, Cadonilimab, nab-paclitaxel, gemcitabine”, 3 entries
- “EndoTAG-1 and Gemcitabine”, 3 entries
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 53 studies
- Carcinoma, Non-Small-Cell Lung, 42 studies
- Breast Neoplasms, 24 studies
- Neoplasms, 10 studies
- Biliary Tract Neoplasms, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.